期刊文献+

分段肺泡灌洗与全肺灌洗治疗肺泡蛋白沉着症患者效果的比较 被引量:2

Comparing the effect of segmental bronchoalveolar lavage and whole lung lavage in treatment of patients with pulmonary alveolar proteinosis
下载PDF
导出
摘要 目的通过对分段肺泡灌洗和全肺灌洗治疗肺泡蛋白沉着症(pulmonary alveolar proteinosis,PAP)患者的疗效及安全性比较,以寻找PAP最有效的治疗方法。方法选取2002年1月~2012年3月昆明市第一人民医院呼吸二科住院的16例PAP患者,分为分段肺泡灌洗(segmental bronchoalveolar lavage,SBL)和全肺灌洗(wholelung lavage,WLL)治疗组。其中SBL治疗组7例,WLL治疗组9例。比较两组灌洗液量、灌洗液回收率、术中及术后并发症方面的差异,以及术后1个月两组在肺功能的一氧化碳弥散量(DLCO)、第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大通气量(MVV)实测值占预计值百分比、氧分压(PaO2)、氧饱和度(SaO2)、Borg呼吸困难评分、6 min步行试验、胸部高分辨率CT(HRCT)上病灶吸收方面的差异。结果 WLL治疗组灌洗液入量、回收率明显高于SBL治疗组,差异有统计学意义(P<0.05)。术中两组均未出现并发症,且术后两组在出现并发症方面无差异(P>0.05)。术后1个月在改善患者肺功能(DLCO%、FEV1%、FVC%、MVV%)、PaO2、SaO2、Borg呼吸困难评分、6 min步行试验、胸部HRCT病灶吸收方面WLL治疗组均优于SBL组,差异均有统计学意义(P<0.05)。结论 WLL较SBL治疗PAP的疗效好,值得在临床推广。 Objective To search the effective treatment for PAP by comparing the curative effect and security of seg- mental bronchoalveolar lavage and whole lung lavage in treatment of patients with pulmonary alveolar proteinosis (PAP). Methods 16 patients diagnosed with PAP were divided into segmental bronchoalveolar lavage (SBL) treatment group and whole lung lavage (WLL) treatment group from two department of respiratory medicine, the First People's Hospital of Kunming City from January 2002 to March 2012. And seven patients were enrolled in SBL treatment group, nine patients were enrolled in whole lung lavage treatment group. The difference of two groups on lavage fluid volume, lavage fluid recovery rate, intraoperative and postoperative complications, and on DLCO%, FEVI%, FVC%, MVV% predicted value in pulmonary function, PaO2, SaO2, borg dyspnea score, six-minute walk test, focus absorption on high resolution CT (HRCT) of chest after one month of post-treatment were compared. Results The lavage fluid vol- ume, lavage fluid recovery rate of WLL treatment group were significantly higher than that of SBL treatment group, the difference had statistical significance (P 〈 0.05). Two groups all did not appear complications during operation, and the postoperative complications of WLL treatment group were lower than that of SBL treatment group, but the differ- ence had no statistical significance (P 〉 0.05). WLL treatment group were superior to the SBL treatment group in im- proving DLCO%, FEV1%, FVC%, MVV% predicted value in pulmonary function, PaQ, SaO2, Borg dyspnea score, six minutes walking test, focus absorption on HRCT of chest after one month of post-treatment, the difference had statisti- cal significance (P 〈 0.05). Conclusion The curative effect of WLL is better than that of SBL, so WLL is worthy popu- larized in clinical.
出处 《中国医药导报》 CAS 2013年第9期59-61,64,共4页 China Medical Herald
基金 云南省昆明市第一人民医院医药卫生科研项目(编号2011KJC10)
关键词 肺泡蛋白沉着症 分段肺泡灌洗 全肺灌洗 Pulmonary Alveolar Proteinosis Segmental Bronchoalveolar Lavage Whole Lung Lavage
  • 相关文献

参考文献16

  • 1Wang BM,Stern EJ,Schmidt RA,et al. Diagnosing pulmonary alveo-lar proteinosis A review and an update [J]. Chest, 1997, 111 :460-466.
  • 2ATS Statement.Guidelines for the Six-Minute Walk Test [J]. Am JRespir Crit Care Med,2002,166: 111-117.
  • 3Rosen SH,Castleman B, Liebow AA,et al. Pulmonary alveolar pro-teinosis [J]. N Engl J Med,1958,258: 1123-1126.
  • 4Seymour JF,Presneill JJ. Pulmonary alveolar proteinosis:progress inthe First 44 Years [J]. Am J Respir Crit Care Med, 2002,166(2):215-235.
  • 5Cordonnier C,Fleury FJ,Escudier E,et al. Secondary alveolar pro-teinosis is a reversible cause of respiratory failure in leukemic pa-tients [J]. Am J Respir Crit Care Med, 1994,149(3) .*788-794.
  • 6Uchida K’Nakata K’Trapnell BC,et al. High affinity autoantibodiesspecifically eliminate granulocytemacrophage colony-stimulating fac-tor activity in the lungs of patients with idiopathic pulmonary alveolarproteinosis [J]. Blood,2004,103(3) : 1089-1098.
  • 7Inoue Y,Trapnell BC,Tazawa R,et al. Japanese Center of the RareLung Disease Consortium. Characteristics of a large cohort of autoim-mune pulmonary alveolar protienosis patients in Japan [J]. Am JRespir Crit Care Med,2008,177(7) :752-762.
  • 8Goldstein LS,Kavuru MS,Curtis Me Carthy P,et al. Pulmonary alve-olar proteinosis:Clinic feature and outcomes [J], Chest, 1998, 114(5):1357-1362.
  • 9Me Donald JW,Alvarez F,Keller CA. Pumonary alveolar proteinosisin association with household exposure to fibrous insulation material[J]. Chest,2000,117(6) :1813-1817.
  • 10Cummings KJ, Donat WE, Ettensohn DB ,et al. Pulmonary alveolarproteinosis in workers at an indium processing facility [J]. Am JRespir Crit Care Med,2010,181(5) :458-464.

同被引文献19

  • 1徐萧洪,宋作庆,范贤明.肺泡蛋白沉积症的研究进展[J].国际呼吸杂志,2006,26(11):856-859. 被引量:25
  • 2Rosen SH, Castleman B,Liebow AA.Pulmonary alveolar pro- teinosis[J].N Engl J Med, 1958,258 (23) : 1123-1142.
  • 3Inoue Y, Trapnell BC,Tazawa R,et al.Characteristics of a large cohort of patients with autoimmune pulmonary alveo- lar proteinosis in Japan[J].Am J Respire Crit Care Med,2008, 177(7) :752-762.
  • 4Doerachuk CM.Pulmonary alveolar proteinosis host defense awry? [J].Clin Immunol, 2010,135 (2) : 223-235.
  • 5Seymour JF, Presnei11 JJ, Schoch OD,et al.Therapeutic ef- ficacy of granulocyte-macrophage colony-stimulating fac- tor in patients with idiopathic acquired alveolar pro- teinosis[J].Am J Respir Crit Care Med, 2001,163(2) : 524.
  • 6Papiris SA,Tsirigotis P,Kolilekas L,et al.Long-term inhaled granulocyte macrophage-colony-stimulating alveolar pro- teinosis:effectiveness,safety,and lowest effective dose [J]. Clin Drug Investig, 2014,34 (8) : 553-564.
  • 7Arai T,Inoue Y,Sugimoto C,et al.CYFRA 21-1 as a disease severity marker for autoimmune pulmonary alveolar pro- teinosis[J].Respirology, 2014,19 (2) : 246-252.
  • 8Takuji S,Paritha A,Takuro S,et al.Pulmonary macrophage transplantation therapy[J].Nature, 2014,514 (7523) : 450- 454.
  • 9徐丹,徐治波,王可,冯玉麟,钟彦.全肺灌洗治疗肺泡蛋白沉着症3例[J].西部医学,2008,20(3):672-673. 被引量:1
  • 10梁雁.全肺灌洗术治疗肺泡蛋白沉积症的观察护理[J].右江医学,2008,36(6):776-777. 被引量:1

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部